Creatine for Depressed Male and Female Methamphetamine Users
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
| Condition(s) | Depression, Anxiety, Methamphetamine Dependence |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression |
| Who can participate | Inclusion Criteria: * Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse * Current diagnosis of major depressive disorder (primary or substance-induced) * Current diagnosis of an anxiety disorder (primary or substance-induced) * Current Hamilton Depression Rating scale score \> or = to 16 * Current Hamilton Anxiety Scale score \> = to 18 * If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation Exclusion Criteria: * Persons unable to provide adequate informed consent * Persons who are at clinically significant suicidal or homicidal risk * Primary substance-related diagnosis other than methamphetamine dependence or abuse * Positive pregnanc |
| Ages | 18 Years to 59 Years |
| Sex | All |
| Lead sponsor | Montana State University |
| Locations | Missoula, Montana, United States |
| Start date | 2015-11 |
| NCT ID | NCT02568878 |
| Official listing | https://clinicaltrials.gov/study/NCT02568878 |